{"entity":{"id":"synnovation-therapeutics","kind":"company","name":"Synnovation Therapeutics","aka":[],"tldr":"Synnovation Therapeutics develops targeted pills for genetically defined cancers. Its PARP1 blocker SNV1521, built to reach the brain, is in early trials including one with a RAS drug in pancreatic cancer; in 2026 Novartis agreed to buy its breast cancer PI3K-alpha programme for USD 2 billion upfront.","summary":"Synnovation Therapeutics, with its main office in Wilmington, Delaware, launched on 24 January 2024 with a USD 102 million Series A led by Third Rock Ventures with Nextech, Lilly Asia Ventures, Sirona Capital and Cormorant Asset Management, to advance small-molecule precision oncology medicines. SNV1521 is a PARP1-selective, brain-penetrant inhibitor; its first patient was dosed on 11 March 2024, phase 1 data were presented at ESMO 2025, and a clinical collaboration with DualityBio on the HER3 antibody-drug conjugate DB-1310 was announced in October 2025. A further phase 1 study combines SNV1521 with the RAS(ON) inhibitor daraxonrasib in advanced pancreatic cancer. SNV4818, a pan-mutant-selective PI3Kα inhibitor, dosed its first patient on 24 February 2025; on 20 March 2026 Novartis agreed to acquire Pikavation Therapeutics, the wholly owned subsidiary holding the PI3Kα programmes, for USD 2 billion upfront and up to USD 1 billion in milestones, with Synnovation keeping SNV1521 and its other subsidiaries. Wenqing Yao is founder and chief executive and Liangxing Wu is co-founder.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.synnovationtx.com/"},{"label":"Launch and Series A release, January 2024","url":"https://www.synnovationtx.com/news/synnovationtherapeuticslauncheswith102milliontoadvanceclinical-stagepipelineofprecision"},{"label":"SNV1521 first patient dosed","url":"https://www.synnovationtx.com/news/parp1-fip-pressrelease"},{"label":"SNV4818 first patient dosed","url":"https://www.synnovationtx.com/news/pi3ka-fip-pr"},{"label":"Novartis to acquire the PI3K-alpha programme, March 2026","url":"https://www.synnovationtx.com/news/novartis-to-acquire-synnovation-therapeutics-pan-mutant-selective-pi3ka-inhibitor-program"}],"tags":[],"related":[],"cancers":["pancreatic","breast-hr-positive"],"sections":["targeted-therapy"],"technologies":["parp-inhibitor","pi3k-akt-mtor-inhibitors","synthetic-lethality-approaches"],"targets":["parp","pik3ca"],"drugs":["snv1521"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06220864","nct07756281","nct06736704"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated. The SNV1521 trials are registered to ParVation Therapeutics, Inc. and the SNV4818 trial to Pikavation Therapeutics, Inc.; Pikavation is named by Synnovation as its subsidiary, while ParVation's relationship is inferred from the synnovationtx.com contact address on the registry entry and was not confirmed on a company page. Whether the Novartis acquisition of Pikavation had closed was not confirmed. The ESMO 2025 response figures were not read on a primary page and are not repeated."],"hq":"Wilmington, DE","country":"US","companyType":"biotech","website":"https://www.synnovationtx.com/","stage":"startup","investors":["third-rock-ventures","cormorant-asset-management"],"funding":[{"round":"Series A","year":2024,"amountUsd":102000000,"source":"https://www.synnovationtx.com/news/synnovationtherapeuticslauncheswith102milliontoadvanceclinical-stagepipelineofprecision","note":"Led by Third Rock Ventures with Nextech, Lilly Asia Ventures, Sirona Capital and Cormorant Asset Management"}]},"route":"/companies/synnovation-therapeutics/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"pi3k-akt-mtor-inhibitors","kind":"technology","name":"PI3K, AKT and mTOR inhibitors","route":"/technologies/pi3k-akt-mtor-inhibitors/"},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/"}],"drug":[{"id":"snv1521","kind":"drug","name":"SNV1521","route":"/drugs/snv1521/"}],"company":[{"id":"cormorant-asset-management","kind":"company","name":"Cormorant Asset Management","route":"/companies/cormorant-asset-management/"},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"},{"id":"third-rock-ventures","kind":"company","name":"Third Rock Ventures","route":"/companies/third-rock-ventures/"}],"trial":[{"id":"nct07756281","kind":"trial","name":"First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer","route":"/trials/nct07756281/"},{"id":"nct06220864","kind":"trial","name":"SNV1521 in Participants With Advanced Solid Tumors","route":"/trials/nct06220864/"},{"id":"nct06736704","kind":"trial","name":"SNV4818 in Participants With Advanced Solid Tumors","route":"/trials/nct06736704/"}]}}